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Abstract 
Pohanka, A., 2006. Antifungal Antibiotics from Potential Biocontrol Microorganisms. 
Doctor’s dissertation 
ISSN 1652-6880, ISBN 91-576-7096-X 
 
This thesis presents isolation and structure elucidation of twenty-five antifungal antibiotics. 
The compounds were isolated from four different microorganisms, which had all been found 
to suppress fungal pathogens in bioassays.  
Eight cyclic depsipeptides, enniatins, were isolated from the fungus Fusarium sp. F31. 
Four of them have not previously been isolated from natural sources. They inhibited 
Botrytis cinerea spore germination at levels down to 100 μg/ml. From the bacterium 
Pseudomonas sp. MF381-IODS, two linear polyene polyketides were isolated, pseudotrienic 
acids A and B, together with the known antifungals didehydro-deepoxirhizoxin, and 
pyrrolnitrin. The pseudotrienic acids inhibited Gram-positive bacteria at levels down to 70 
μg/ml. The Pseudomonas sp. Ki19 strain produced four different dialkylresorcinols, of 
which two were new analogues. All four were active against fungi at levels down to 100 
μg/ml, and also against Gram-positive bacteria down to 5 μg/ml. The actinomycete 
Kutzneria sp. 744 was found to produce a spectrum of nine di- and trichlorinated cyclic 
depsipeptides, containing several unusual amino acids. The trichlorinated compounds were 
significantly more active and inhibited fungi down to 60 μg/ml and Gram-positive bacteria 
down to 5 μg/ml 
A robust sample work-up method was developed for isolation of antifungal metabolites 
from both fungi and bacteria. It consisted of bioassay-guided isolation by solid phase 
extraction (SPE) and HPLC. The bioassay was based on inhibition of fungal spores or 
bacterial cells and was able to detect compounds with a range of antifungal activities. Such 
a multi-target functional bioassay was used in order to isolate compounds with several types 
of antifungal mechanisms. Bacteria were included in the bioassays in order to gain a broader 
knowledge of the antibiotic spectrum.  
The structural elucidation of the compounds relied on NMR and MS techniques together 
with chemical degradation and derivatization methods, and GCMS analysis for 
stereochemical investigation. The absolute configuration was determined for all previously 
unpublished compounds. 
 
Keywords: antifungal activity, depsipeptides, polyketides, dialkylresorcinols, Marfey’s 
method, enantiomeric resolution, Pseudomonas, Fusarium, Kutzneria, bioassay-guided 
isolation 
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Appendices 
A   Taxonomic names of organisms 
 
B   Papers I-IV 
 
The present thesis is based on the following papers, which will be referred to by 
their Roman numerals: 
 
I.  Pohanka, A., Capieau, K., Broberg, A., Stenlid, J., Stenström, E., and Kenne,  
L. 2004. Enniatins of Fusarium sp. strain F31 and their inhibition of Botrytis 
cinerea spore germination. Journal of Natural Products, 67 (5), 851-857. 
 
II  Pohanka, A., Broberg, A., Johansson, M., Kenne, L., and Levenfors, J. 2005. 
Pseudotrienic acids A and B, two bioactive metabolites from Pseudomonas sp. 
MF381-IODS, Journal of Natural Products, 68 (9): 1380-1385. 
 
III  Pohanka, A, Levenfors, J., and Broberg, A. 2006. Antimicrobial 
dialkylresorcinols from Pseudomonas sp. Ki19. Journal of Natural Products, 
69 (4). 654-657. 
 
IV Pohanka, A., Menkis, A., Levenfors, J., and Broberg, A. Low abundance 
kutznerides from Kutzneria sp. 744 and antimicrobial activities of kutznerides 
1-9. Manuscript. 
 
Papers I-III are reproduced with permission from Journal of Natural Products. 
Copyright 2004, 2005, 2006 American Chemical Society. 
 
Contributions for Papers I-IV: 
 
The projects were all co-operations between chemists and biologists. All biological 
work, such as growth of organisms, bioassays, and sequencing was done by the 
biologist co-authors. The HRMS measurements in Papers I-IV were performed by 
Suresh Gohil. 
 
I  I initiated and designed the project in collaboration with Kristof Capieau. All 
chemical work was performed by me and also the major part of the writing. 
 
II  I initiated and designed the project in collaboration with Maria Johansson. I 
performed all chemical work except absolute configuration of the amino acid 
moiety of pseudotrienic acid, which was done by Anders Broberg. The major 
part of the writing was performed by me. 
 
III  I initiated and designed the project in collaboration with Jolanta Levenfors. All 
chemical work was performed by me and also the major part of the writing. 
 
IV  I took part in expansion of the project leading to the paper. All chemical work 
was performed by me and also the major part of the writing. 
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Abbreviations and symbols 
A b s          a b s o r b a n c e  
A A          a m i n o   a c i d  
AWB        asexual  white  basidiomycete 
A U          a r b i t r a r y   u n i t s  
 
BCA        biocontrol  agent 
BuOH      butanol 
 
C D          c i r c u l a r   d i c h r o i s m  
COSY      correlation  spectroscopy 
 
δ          c h e m i c a l   s h i f t  
DNA        deoxyribonucleic  acid 
 
EF2         elongation  factor  2 
EIMS        electron  impact  mass  spectrometry 
ESIMS       electrospray  ionisation  mass  spectrometry 
 
FAB        fast  atom  bombardment 
FT-ICR       Fourier  transform  ion  cyclotron  resonance 
 
GC         gas  chromatography 
GRAS      generally  regarded  as  safe 
 
HA         hydroxy  acid 
HPLC      high  performance  liquid  chromatography 
HMBC       heteronuclear  multiple  bond  correlation 
HSQC      heteronuclear  single  quantum  coherence 
 
IODS        isolates  having  characteristic  optically  denser  spots 
ITS         internal  transcribed  spacer 
IPC         inositol  phosphoceramide 
 
J           coupling constant 
 
MALDITOF  matrix assisted laser desorption/ionisation 
time-of-flight 
MeCN      acetonitrile 
M e O H        m e t h a n o l  
M H z         m e g a h e r t z  
MIC       minimal  inhibitory  concentration 
mRNA       messenger  RNA 
M S          m a s s   s p e c t r o m e t r y  
 
NMR        nuclear  magnetic  resonance 
NOE        nuclear  Overhauser  effect 
N O E S Y        n u c l e a r   O v e r hauser effect spectroscopy 
NRPS        nonribosomal  peptide  synthetase 
 
ODS        octadecyl-bonded  silica 
OSMAC     one  strain  –  many  compounds   8
PPFM      pink  pigmented  facultative  methylotroph 
PSD       post  source  decay 
pv.         pathovar 
 
R I         r e f r a c t i v e   i n d e x  
RNA        ribonucleic  acid 
ROE        rotating  frame  nuclear  Overhauser  effect 
ROESY       rotating  frame  nuclear Overhauser effect spectroscopy  
R P          r e v e r s e d   p h a s e  
r R N A         r i b o s o m a l   R N A  
 
sp.         species  (singular) 
SPE       solid  phase  extraction 
s p p .          s p e c i e s   ( p l u r a l )  
 
TLC       thin  layer  chromatography 
 
UV         ultraviolet 
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1. Introduction 
Fungi have fundamental functions in terrestrial ecosystems, in degradation of 
organic matter and in nutrient uptake of plants through mycorrhizal interactions. 
From a human point-of-view, there are both good and bad fungi. There are quite 
some delicious edible fungi and other are used in production of food like soy 
sauce, tempe, and bread. They are also a source of important drugs like the 
penicillins, the cholesterol-lowering lovastatin, and the cyclosporins, which 
counteracts the rejection of transplanted organs.  
On the downside, fungi cause enormous economic loss in agriculture and food 
industry by destroying crops and plants in the field and during storage. In addition, 
many also produce mycotoxins which are harmful to humans and livestock. To a 
certain extent, pathogens can be controlled by sound agriculture and silviculture, 
e.g. maximum use of suppressive soils, crop rotation and removal of potential 
inocula, but all these have a limited effect. When combating fungal pathogens a 
wide array of antifungal agents have been and are being used. They include 
inorganic and synthetic organic compounds, but also antifungal antibiotics and 
compounds based on natural products. Many of these can keep fungal infections at 
an acceptable level but there are several concerns. Some, mainly synthetic agents, 
can accumulate in nature if biodegradation is slow or even missing, other are toxic 
not only to fungi but to other organisms as well, including humans, and all have 
the potential of losing their effect as the targeted pathogens develop resistance. 
This means that there will probably never be a perfect antifungal agent, a magic 
bullet, which kills the pathogen every time and leaves the treated organism and the 
rest of the environment unharmed. There will always be a need for new agents and 
new ways of controlling fungal pathogens.  
One alternative way to maintain populations of pathogenic fungi at low levels is 
by biocontrol agents, i.e. organisms that act as natural enemies to the fungi. 
Various microorganisms have been investigated as potential antifungal biocontrol 
agents (BCAs) and several have been launched on the market.
1  
The high expectations put on BCAs are the result of several factors. The agents 
can have multiple modes of action, which can make the pathogen less prone to 
develop resistance. Modes of action of BCA that have been put forward are 
competition for nutrients and space, induction of the hosts own defense against 
pathogens (induced systemic resistance), interference with the chemical signaling 
of the pathogen, parasitism, and production of antifungal metabolites.
2,3 The 
mode(s) of action that are the most important ones probably depends on the 
specific host plant, biocontrol agent, and pathogen combination.  
Another benefit of BCAs is that they can be able to propagate in field. Fewer 
treatments might then be needed during a growth season compared to chemicals. If 
antifungal antibiotics are produced by the agent, there will be less risk of 
bioaccumulation, as paths of biodegradation will be present in nature.  
When developing potential biocontrol agents it is crucial to investigate the 
production of any possible antifungal antibiotics. New antifungal metabolites may 
have new modes of action and, even if the investigated organisms are not suitable 
for development to a BCA product, the metabolites can still be potential lead  
 Good toxicity profile?
Suppression of pathogens in field trials?
N Y N Y
N Y N Y
N Y
N Y
New structures?
N Y
Production of antibiotics?
Potential biocontrol microorganism
Biocontrol agent
TERMINATION Lead compound
 
Fig. 1. Work flow for chemical investigation of potential biocontrol microorganisms, with 
the possible outcomes at the bottom. The work in this thesis deals with the area marked by 
the dotted rectangle.  
 
compounds for new compound-based antifungal agents. If the potential biocontrol 
organism  is suitable for development to a product, registration of a biocontrol 
product within the European Union requires investigation of mode of action, 
production of any antifungal metabolites and their toxicity profile, and a 
corresponding investigation of other significant metabolites.
4,5 For BCA 
registration in the USA, discussions and experimental findings along the same 
lines need to be presented.
6-8  
This thesis deals with chemical investigation of potential biocontrol 
microorganisms and is a part of the research program Microbial Antagonism 
against Fungi (MAaF), which started in 1996. The goal of the program was to find 
potential antifungal biocontrol agents for the food and feed industry and in 
agriculture and silviculture. Chemical investigation of potential biocontrol strains 
is a venture which has several goals, that all have to be weighted against each 
other. In the end, a new BCA may be developed or a new lead compound may be 
fed into the agrochemical or pharmaceutical industry, or possibly both (Fig. 1). 
 
  10  11 
2. Scope of the thesis 
The overall scope of this thesis was to isolate antifungal compounds from 
microorganisms exhibiting antifungal activity.  
Selection of microbial strains for chemical investigation was mainly based on 
activity in antifungal bioassays. As several different strain collections were 
utilized, it was expected that both fungi and bacteria were to be investigated. In 
order to make this possible, it was needed to develop a robust bioassay-guided 
isolation method that could function with both fungal and bacterial strains (applied 
in Papers I-IV). 
In this thesis, four projects are included. They are based on isolation of 
antifungal antibiotics from phyllosphere fungi (Paper I), rhizosphere bacteria 
(Papers II, III), and from mycorrhizal root bacteria (Paper IV) 
 
3. Definitions 
The title of this thesis contains the terms antibiotic, biocontrol and microorganism 
which all have a broad use in different scientific fields. The mycologist Selman 
Waksman defined the noun antibiotic in 1947 as 
  
“a chemical substance, produced by micro-organisms, which has the 
capacity to inhibit the growth of and even to destroy bacteria and other 
micro-organisms. The action of an antibiotic against micro-organisms is 
selective in nature”
9  
 
This definition is still valid and will be used in the thesis. The addition of 
antifungal in antifungal antibiotic highlights the antibiotics ability to be 
detrimental to one or several fungal taxa. The more-inclusive term antifungal 
compound can be used when referring to both natural products and synthesized 
antifungal compounds. The even broader term antifungal agent also includes 
antifungal biocontrol agents.  
The term biocontrol will be used in the definition put forward by Paul DeBach in 
1964:  
 
“The action of parasites, predators, or pathogens in maintaining another 
organism’s population density at a lower average than would occur in 
their absence.”
10 
 
There is no scientific definition of microorganism, although the term can be 
clarified to a certain degree. A usable circumscription of a microorganism is that it 
is a microscopic organism with no or low cell differentiation capable of living as a 
single cell in its natural habitat. With this definition, bacteria, unicellular algae, 
protozoae and microscopic fungi, including yeasts, all count as microorganisms. 
However, some of these organisms can aggregate to form multicellular 
differentiated macroscopic structures, especially fungi and algae. All 
microorganisms dealt with in this thesis are either bacteria or fungi.    12
An individual microorganism can most often be determined to belong to a 
specific genus. Species definition, however, is never straightforward in any 
organism group and for microorganisms such as fungi, and especially bacteria, it 
can be even harder due to their genome flexibility. If unambiguous identification 
can not be done, an organism can instead be given an individual strain designation 
for identification. In this thesis, strain is used in the meaning of a microorganism 
isolate originating from a single isolated cell or spore. The strain can in turn be 
identified to the level of family or genus. 
The taxonomy of bacteria and fungi is under constant revision. Species and 
genera can be split, clumped together, moved to other families or be established on 
new taxonomic levels. Old well-known species names are sometimes used 
although they have no standing in nomenclature, as new names can be hard to 
implement. In this thesis, the scientific names in the original references are 
conserved for ease of recognition, and any taxonomical name changes as of 2005 
are included in Appendix A. 
 
4. Antifungal antibiotics 
Natural products are an important source of new bioactive compounds and for the 
drugs launched over the period 1981-2002, Newman et al.
11 found that 40% were 
either natural products as is, or modified natural products. In the case of 
antifungals the share was much lower, 14%, mainly because of the azole, 
allylamine and morpholine synthetic antifungal compounds. In agriculture, 
Pachlatko estimated that natural products had only about 10% of the market for 
crop-protection
12, and thus, the share for antifungal antibiotics was even smaller.  
 
4.1 Control of fungal pathogens on plant and man 
Research on new agents for controlling fungi has been a concern both for the 
agricultural and pharmaceutical industry. This is not least seen in the mergers of 
pharmaceutical and agrochemical companies like the formation of Novartis in 
1996 from Ciba-Geigy and Sandoz and the merger of Astra and Zeneca to 
AstraZeneca in 1999. Although the knowledge on antifungal antibiotic compounds 
is shared between the two areas there are important differences. 
 
4.1.1 Pathogens 
Important pathogens on humans are Candida albicans, Cryptococcus neoformans, 
and Aspergillus fumigatus
13 while important pests in agriculture are Fusarium spp., 
Botrytis spp., and Rhizoctonia solani together with the oomycetes Phytophthora 
infestans and Pythium spp. The activity of many antifungal antibiotics is specific 
and inhibition of one fungal pathogen does not immediately imply that it can 
inhibit another. 
   13 
4.1.2 Compound stability and physical properties 
Agricultural products need to be compatible with automated administration and 
sufficiently stable to sun irradiation. In developing drugs for humans, other criteria 
have to be met, such as formulation and stability to the gut environment. 
 
4.1.3 Costs 
In agriculture, the investment spent on controlling fungal pathogens needs to be 
balanced by the effect on the harvest. A rough estimate of the maximum possible 
investment in 1998 was 25-50 US dollars/hectare.
12 In contrast, treatment of 
human mycosis in industrialized countries is more limited by the choice of 
available drugs than their costs. In comparison, development of a new 
agrichemical is estimated to take at least four and as much as ten years and cost 
150-250 million US dollars
14,15 while a new drug takes ten to fifteen years with an 
average cost of 800 million US dollars.
16 Development of a biocontrol agent has 
been estimated to take as little as three years at an average cost of 6 million US 
dollars.
17 Note that costs for agrochemicals and biocontrol agents are estimates 
from industrial sources, while the drug cost is based on academic evaluation. 
 
4.1.4 Human toxicity 
In developing new pharmaceuticals, toxicity to humans is closely followed, not 
least if the goal would be an oral drug (systemic drug). For treatment of critical 
illness, toxicity can be accepted as for the standard antifungal agent amphotericin 
B, nicknamed “ampho-terrible”
18, which cause severe kidney injuries.  
In agriculture, low toxicity is also a priority, not only to humans but also towards 
plants and other non-harmful organisms in the field. Human toxicity of agricultural 
agents can partly be dealt with by careful handling and letting the last treatment 
have time to wash away or degrade before harvest. In silviculture, however, the 
main risk is the actual handling of the agent. Biocontrol agents have a potential for 
controlling fungal infections in the field, and for humans, similar broad 
prophylactic treatment is feasible. For example, the use of Lactobacilli as 
probiotics is based on their assumed biocontrol ability. Treatment of developed 
systemic human fungal infections with BCAs, does not seem likely in the near 
future as the treatment of an infection with essentially another infection is still a 
too unknown system to control.  
 
4.2 Microbial sources 
In the early history of antibiotics, a variety of bacterial and fungal strains were 
investigated with a majority coming from rhizosphere samples from temperate 
regions. When streptomycin was discovered in 1944, the main focus turned to 
streptomycetes. They were found to produce a wide spectrum of structurally 
diverse bioactive secondary metabolites. During the fifties and sixties, as much as 
70% of the reported antibiotics were isolated from this genus. The main change 
since then has been an increase of compounds isolated from fungi and rare 
actinomycetes (i.e. non-Streptomyces actinomycetes).
19 In addition, investigation   14
of organisms from new habitats or organism groups, and new selection strategies 
has been presented for improving isolation of new chemical entities. Organisms 
that inhabit unique niches or areas of high biodiversity should have a high 
probability of producing unique metabolites. One such area is the marine 
environment. Although there is much focus today on marine natural products 
chemistry, large scale investigation of marine microorganisms started as late as in 
the seventies. Since then, many antifungal compounds of marine origin have been 
reported and there are probably many more to come.
20,21 
Microorganisms which live under harsh conditions, so called extremophiles, also 
have a potential for producing unique metabolites.
22 They can be found in, for 
example, deep sea vents (black smokers), in permafrost, in alkaline or saline lakes, 
or hot springs. Their adaptations to extreme physical environments have inevitably 
affected their biosynthetical abilities.  
Another specialized habitat is inside other organisms. It has been shown that 
many plants harbor endophytic microorganisms that can contribute to the 
metabolic content of the plant tissue.
23 These endophytes have a high degree of 
specialization, and it is possible that many plant species may have their own 
endemic species. There is thus a vast biochemical diversity to investigate in these 
microorganisms. 
Although isolation of microorganisms from previously uninvestigated biotopes 
will yield many new bioactive compounds, estimates propose that only a small 
fraction (0.1-1%) of all microorganisms can be isolated and propagated with 
standard culturing conditions.
24 There is thus a large genetic diversity that might 
not be realized. This can be approached by specializing isolation and growth 
conditions
25 or by metagenomics, i.e. by inserting biosynthesis genes of 
uncultivable microorganisms in modified producer organisms.
26,27  
Genetic methods can also be useful for evaluating the biosynthesis potential of 
microorganisms. They can be screened for known biosynthesis genes or gene 
regions and in the best-case scenario, qualified suggestions can be made of which 
compounds the strain can produce. This has been done successfully for polyketide 
synthase gene sequences. The approach will improve as more sequencing data of 
known producer strains will become present.
28,29  
Nevertheless, one should not abandon the more easily accessible 
microorganisms. Some of these, like streptomycetes  and pseudomonads, are 
capable of producing a spectrum of chemically diverse metabolites, and can be 
said to be metabolically talented. By changing the culturing conditions for such 
strains, different metabolic outputs can be obtained, and even new compounds can 
be isolated. This approach is known as OSMAC (one strain – many 
compounds).
30,31  
 
 
 
 
 4.3 Structural diversity of antifungal antibiotics 
Antifungal antibiotics display a wide structural diversity and their modes of action 
target a number of fungal enzymes and physical structures. In the overview below, 
they are presented according to compound class. Original articles for isolation and 
structure elucidation are cited as far as possible. 
 
4.3.1 Carbohydrates 
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Fig. 2. Streptomycin. 
 
The streptomycins (Fig. 2) were isolated for their antibacterial properties and 
proved effective against the much feared human pathogen Mycobacterium 
tuberculosis, the cause of tuberculosis. The bactericidal effect is based on 
inhibition of protein synthesis. Streptomycin binds to the ribosome, and causes 
misreading of the genetic code.
32 This, in turn, permits even more influx of the 
compound to the bacterium cytosol. They were originally isolated from strains of 
Streptomyces griseus in 1944
33, and were also found to be effective for controlling 
fungal pests on pears, apples and tobacco.
34 
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Fig. 3. Kasugamycin. 
 
The disaccharide kasugamycin (Fig. 3) was isolated from Streptomyces 
kasugaensis in 1965
35 and the structure was elucidated the year after.
36 It blocks 
protein synthesis and shows low toxicity to humans.
12 Kasugamycin is used for 
treatment of Pyricularia oryzae but as the pathogen rapidly develops resistance to 
the compound, it is used combination with other fungicides.
1 
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Fig. 4. Validamycins. 
 
The validamycin group of antifungal antibiotics (Fig. 4) were discovered from a 
culture of Streptomyces hygroscopicus in 1970.
37,38 The target pathogen was 
Rhizoctonia solani and validamycin A and B were later found to control R. solani 
on cucumbers in the field. Structure elucidation revealed that they were 
aminotrisaccharides.
39-41 The compounds are metabolized in fungal cells to 
validoxylamines, trehalose analogues (Fig. 5), which inhibit the enzyme 
trehalase.
42 The trehalase enzyme is needed for regulation of trehalose levels in the 
fungal cell. Trehalose is thought to be critical in stress metabolism, and for cell 
wall stability.
43,44  
 
OH
OH
OH
HO
HN
OH
OH
R
HO
HO
OH O
OH
OH
HO
O HO
HO
O
OH
OH
 
 R     
Validoxylamine A  H    Trehalose 
Validoxylamine B  OH     
 
Fig. 5. Validoxylamines, trehalose analogues which inhibit the enzyme trehalase.  
 
 
 
 
 
 
 
 
 
  164.3.2 Amino acids and peptides 
Single amino acids as well as peptides and proteins have been found to have 
antifungal activities. The cyclic β-amino acid cispentacin (Fig. 6) was isolated 
from Bacillus cereus in 1989
45 and the year after under the name FR109615 from 
Streptomyces setonii.
46,47 Cispentacin acts by interfering with amino acid 
metabolism as well as by inhibiting isoleucin-tRNA synthase.
48 The synthetic 
cispentacin analogue BAY 10-8888/PLD-118 (Fig. 6) has entered clinical trials for 
treatment of candidiasis.
49  
 
H2N CO2H H2N CO2H 
 
Fig. 6. The amino acid cispentacin (left) and its synthetic analogue BAY 10-8888/PLD-118 
(right). 
 
A large group of cyclic peptides, lipopeptides and lipodepsipeptides (containing 
one or several ester bonds) have been isolated on their antifungal activity, and they 
act by several different modes of action. Of the antifungal cyclic peptides, 
aureobasidin has gained much attention since its discovery in 1991.
50  
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Fig. 7. Aureobasidin. 
 
Aureobasidin (Fig. 7) was isolated from the fungus Aureobasidium pullulans 
and was found to inhibit the enzyme inositol phosphoceramide (IPC) synthase 
which is critical in fungal sphingolipid biosynthesis. Sphingolipids, in turn, are 
vital for the function of the cell membrane for fungi and humans alike. The IPC 
enzyme, on the other hand, is lacking in mammals, which means that all 
compounds selectively inhibiting IPC are highly interesting for development of 
antifungal drugs. 
The echinocandins are cyclic lipohexapeptides (Fig. 8) which interfere with the 
fungal glucan synthesis through inhibiting the β-1,3-D-glucan synthase enzyme 
complex.
51 β-1,3-D-glucan is a major constituent of the outer parts of the fungal 
cell wall. The earliest member of the class to be isolated was echinocandin B. The 
compound was discovered from a strain of the fungus Aspergillus nidulans var. 
echinulatus in 1972 in a random screening at Ciba-Geigy.
52 Researchers at Sandoz 
  17 had independently isolated echinocandin B at about the same time and they 
published the full structure from a sample produced by Aspergillus rugulosus.
53 
 
1
4
3
O N
O 5
2
H
N N
N
H
H
N N
N
H
H2C
O O
O
O O
O
H
N
HO
R1
R2
OH HO
R4
OH
OH
OH
R5
O
HO R3
OH
O
R5
 
 
 R 1 R2 R3 R4 R5
Aculeacin Aγ OH CH3 CH3 H 1 
Echinocandin B  OH  CH3 CH3 H 2 
Anidulafungin OH  CH3 CH3 H 3 
Pneumocandin B0 OH H  CH2CONH2 H 4 
Caspofungin NHCH2CH2NH2 H CH2CH2NH2 H 4 
WF11899A
54 OH  CH3 CH2CONH2 OSO3H 1 
Micafungin OH  CH3 CH2CONH2 OSO3H 5 
 
Fig. 8. Echinocandin-type antifungal antibiotics and their semisynthetic derivatives.
 
Anidulafungin is a semisynthetic derivative of echinocandin B while caspofungin is based 
on a pneumocandin core. Micafungin is a semisynthetic derivative of WF11899A. 
 
Echinocandins and related compounds (Fig. 8) like pneumocandins
55,56 and 
aculeacins
57 have been used as lead structures in drug development. Three semi-
synthetic derivatives have been marketed as systemic antifungal drugs for human 
use, caspofungin in 2001, micafungin in 2002, anidulafungin in 2006. The two 
first are targeted against invasive aspergillosis, while anidulafungin is used for 
treatment of candidiasis.  
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Fig. 9. Examples of cyclic lipodepsinonapeptides produced by Pseudomonas syringae. 
 
The bacterium Pseudomonas syringae pv. syringae has been the source of a 
number of lipodepsinonapeptides: syringomycins,
58,59 syringotoxins,
60,61 
syringostatins,
62 and pseudomycins (Fig. 9).
63,64 They are thought to interact with 
the fungal cell membrane by pore formation, which results in fatal electrolytic 
leakage.
65 The structures were elucidated in the late eighties and early nineties
59 
and they show activity against Candida spp. and Aspergillus spp. 
For a more detailed account of antifungal and antimicrobial peptides and 
lipopeptides, see the reviews of Balkovec,
66 de Lucca and Walsh,
67 and Chen.
13 
For an introduction to antifungal proteins, see the review of Theis and Stahl.
68 
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Fig. 10. Sordarin. 
 
Sordarin (Fig. 10) was isolated from the fungus Sordaria araneosa and patented in 
1969 through Sandoz. Two years later, the isolation procedure and structure was 
published.
69 The compound consists of the tetracyclic diterpene aglycone 
sordaricin and a glycosyl moiety. Several natural analogues with different 
glycosylation units were isolated in the nineties and showed potent activity against 
certain Candida spp.
70,71 The compounds interrupt protein synthesis in the fungus 
by inhibiting one of the protein elongation factors, EF2. Mammalian cells are not 
effected.
72 
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Fig. 11. Polar triterpenes inhibiting the enzyme β-1,3-D-glucan synthase.  
 
A group of polar triterpenes were reported in year 2000, from a screening 
program aimed at finding inhibitors of β-1,3-D-glucan synthase (Fig. 11). They 
include the fungal metabolites enfumafungin  from a Hormonema sp.,
73,74 
ascosteroside  from  Ascotricha amphitricha,
75 arundifungin from Arthrinium 
arundinis
75,76 and ergokonins from Trichoderma koningii.
77  
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4.3.4 Polyketides  
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Fig. 12. Griseofulvin. 
 
The polyketide griseofulvin (Fig. 12) is considered as the first compound isolated 
on its antifungal properties. It was isolated from Penicillium griseofulvum in 
1939,
78 with structure elucidation performed some years later.
79 The compound 
was shown to be active against Botrytis alli, which causes neck rot in onions, and 
it has been used for treating Botrytis infections in agriculture.
34 The compound was 
launched in 1958 as the first systemic fungicide in treatment of human mycosis.
80 
It is fungistatic and inhibits cell division at higher concentrations through 
destabilization of the microtubuli, possibly in the same way as other antimitotic 
compounds such as vinblastine and paclitaxel.
81  
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Fig. 13. Pradimicins and benanomicins. 
 
Pradimicins,
82 and benanomicins
83,84 are glycosylated benzonaphthacene-
quinones (Fig. 13) and were independently isolated by two research groups in 
1988 from actinomycetes. They bind to the mannan part of mannoproteins which is 
present at the cell surface on many fungi. Binding is followed by rupture of the 
fungal cell membrane. The glycone is responsible for mannan association while 
the carboxylic acid is needed for fungal cell rupture.
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Fig. 14. Khafrefungin. 
 
  21 The linear polyketide khafrefungin (Fig. 14) was isolated from an unidentified 
deuteromycete
86,87 in 1997 and was found to interfere with sphingolipid 
biosynthesis by inhibiting inositol phosphoceramide (IPC).  
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Fig. 15. Australifungin. 
 
Australifungin (Fig. 15), from Sporormiella australis,
88,89 was isolated in the 
same screening project as khafrefungin, but as an inhibitor of ceramide synthase. 
This enzyme is placed one step earlier than IPC in sphingolipid biosynthesis. 
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Fig. 16. The antifungal macrolides amphotericin B and nystatin A1. Commonly,  
nystatin A1 is called only nystatin. 
 
Polyketide macrolides and polyene macrolides have been much investigated for 
antifungal activity and the latter contain some of the most important antifungal 
drugs for human use, amphotericin B and nystatin (Fig. 16). 
Nystatin was isolated from a soil actinomycete in 1950 by Hazen and Brown.
90 
They named it fungicidin after its prominent property, but later renamed it to 
nystatin. It could be used to treat systemic fungal infections in humans as well as 
be used as a topical antifungal, but finding a good formulation for oral 
administration has been a problem till this day. In 1956, amphotericin B was 
isolated by Gold et al.
91 and this compound was launched as an oral antifungal 
drug in 1960. This was to be the standard treatment of systemic mycosis until the 
eighties, when synthetic antifungal antibiotics such as imidazoles and triazoles 
were launched. Both nystatin and amphotericin B are 37-membered macrolactones 
containing a cyclic hemiketal.
92-94 The polyenes bind irreversibly to ergosterol, 
which is a major constituent of the fungal cell wall. The cell wall is destabilized, 
possibly by pore formation by polyene octomers, which causes cell leakage.
95 
Many more antifungal polyenes have been isolated from natural sources,
96 but few 
  22have been applied as agricultural antifungal agents because of their 
photosensitivity and easy oxidation.
34  
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Fig. 17. Natamycin. 
 
The epoxide polyene natamycin (Fig. 17) is an exception.
97 It was isolated in 
1957 from Streptomyces natalensis under the name pimaricin
98 and from 
Streptomyces chattanoogensis under the name tennecetin.
99 It is used for treating 
Fusarium oxysporum basal rots in ornamental plants.
1  
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Fig. 18. Soraphen A.
 
Soraphen A (Fig. 18) is an 18-membered macrolide isolated from the 
myxobacterium Sorangium cellulosum in 1994.
100 Several agricultural pathogens 
could be controlled by the compound, including Erysiphe graminis,  Gerlachia 
nivalis and Botrytis cinerea. It was found to inhibit the fungal acetyl coenzyme A 
carboxylase
101 but had no effect on the corresponding plant enzyme. However, it 
did inhibit the corresponding mammalian enzyme. Together with an discouraging 
toxicity profile, this disqualified it as an agricultural antifungal antibiotic.
12 
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Fig. 19. Rustmicin or galbonoid. 
 
Rustmicin
102/galbonolid
103,104 (Fig. 19) is a 14-membered macrolide found to 
inhibit the sphingolipid IPC synthase. It has been isolated from the bacteria 
Micromonospora chalcea and Streptomyces galbus  
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Fig. 20. Rhizoxin. 
 
The antifungal activity of the 15-membered macrolide rhizoxin (Fig. 20) is based 
on interference with microtubuli dynamics.
105 Rhizoxin and analogues were 
isolated from a fungal Rhizopus chinensis strain
106,107 but have also been found in 
cultures of Pseudomonas (Paper II). 
 
4.3.5 Fatty acids and fatty acid mimics 
 
NH2 O
O
CO2H
CO2H
O
OH
O
HO2C
CO2H  
Fumonisin B1        
CO2H
NH2
OH
OH
OH
OH  
Sphingofungin B           
CO2H
OH HO2C O
HN O
R CO2H  
 R    R    R 
Viridiofungin A 
OH  
B 
 
C 
HN
 
 
Fig. 21. Sphingolipid biosynthesis inhibitors. 
 
Several structures with fatty acid or fatty acid-like moieties have been isolated as 
antifungals, specifically in conjunction with screening for inhibition of enzymes 
connected with sphingolipid biosynthesis.
108 These include the fumonisins from 
  24Fusarium moniliforme,
109,110 the sphingofungins from Aspergillus fumigatus,
111-113 
viridiofungins from Trichoderma viride
114-116 and myriocin
117/ISP-I
118,119 from 
Myriococcum albomyces/Isaria sinclairii (Fig. 21). 
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Fig. 22. Papulacandin D, a representative of the papulacandin glycolipids. 
 
The papulacandin glycolipids (Fig. 22), on the other hand, inhibit glucan 
biosynthesis. They were isolated from a Aspergillus aculeatus strain in 1977.
120-122 
 
4.3.6 Nucleoside analogues 
Although the following compounds all can be described as nucleoside analogues, 
the suggested mechanism of antifungal activity is not in all cases interference with 
DNA/RNA dynamics. 
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Fig. 23. Blasticidin S.
 
Blasticidin S (Fig. 23), a metabolite of Streptomyces griseochromogenes, was 
isolated in 1958
123 and has been used commercially for control of Pyricularia 
oryzae from the early sixties up till today.
1,124 The compound blocks protein 
synthesis in both prokaryotic and eukaryotic cells.
125 Blasticidin S has toxic and 
phytotoxic effects and the use dropped when alternatives like kasugamycin became 
available.
12  
Polyoxin A (Fig. 24) was isolated in 1965 on a sample from a Streptomyces 
cacaoi strain.
126 The structure of polyoxin A and several analogues were published 
shortly afterwards.
127,128 They selectively inhibit the fungal enzyme chitin 
synthetase, which polymerizes N-acetylglucosamine to chitin.
125 Chitin is a major 
constituent of the cell wall core in most fungi, This specific mechanism of the 
polyoxins is highly interesting for drug development as chitin is not present in 
human cells. In agriculture the polyoxins are effective for treatment of a variety of 
fungal pathogens, especially Alternaria spp. and Botrytis cinerea [polyoxin B (Fig. 
24)], and P. oryzae [polyoxin D (Fig. 24)].
1 
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Fig. 24. Polyoxins from Streptomyces cacaoi. 
 
A polyoxin-like group of antifungal (and bonus acaricidal) compounds with 
similar mechanism of action are the nikkomycins. The first compound, nikkomycin 
Z (Fig. 25), was isolated from Streptomyces tendae in 1970 with structure 
elucidation some years later.
129 Nikkomycins were developed as promising 
agricultural antifungals but research was terminated for cost reasons.
12 
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Fig. 25. Nikkomycin Z (left), is a mimic of UDP-N-acetyl-D-glucosamine (right) which is a 
buiding block in chitin synthesis.  
 
Despite large efforts in drug development, no candidate has yet entered clinical 
trials although nikkomycin Z shows promising preclinical results in combination 
with fluconazole.
130 For an in-depth picture of the development of the polyoxins 
and nikkomycins, se the review of Zhang and Miller.
131 
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Fig. 26. Mildiomycin. 
 
Mildiomycin (Fig. 26) is yet another peptidyl nucleoside. It was isolated from a 
strain of Streptoverticillium rimofaciens in a project targeted against Erysiphe 
graminis.
132-135 and it acts by inhibiting fungal protein synthesis.
125 
  264.3.7 Other biosynthetic origin 
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Fig. 27. Cycloheximide. 
The compound cycloheximide (Fig. 27), also called actidione, was isolated as a 
minor component in a streptomycin-producing strain of Streptomyces griseus in 
1946
136 and its structure was published two years later.
137,138 The compound 
selectively inhibits protein synthesis in eukaryotic cells through blocking 
translation of mRNA. It has been used in agriculture and silviculture but due to its 
high phytotoxicity it is a less-than-ideal antifungal agent.
34,124  
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Fig. 28. Pyrrolnitrin and two synthetic analogues, fenpiclonil and fludioxonil. 
 
The small tryptophan derived antifungal antibiotic pyrrolnitrin
139 (Fig. 28) was 
isolated in 1964 from a strain of Pseudomonas pyrrocina.
140 The compound was 
found to be sensitive to light and analogues were synthesized at Ciba-Geigy to 
enhance its photostability. The efforts resulted in the two agricultural commercial 
compounds fenpiclonil and fludioxonil (Fig. 28) used in seed coating.
12 
Pyrrolnitrin acts by inhibiting mitochondrial respiration.
141,142 
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Fig. 29. Strobilurin A and B and the synthetic analogue kresoxim methyl. 
 
The β-methoxyacrylic acid strobilurin A (Fig. 29) was first isolated in 1967 from 
a strain of Oudemansiella mucida under the name mucidin
143 and later 
independently isolated from Strobilurus tenacellus together with strobilurin B (Fig. 
29).
144 The strobilurins inhibit mitochondrial respiration in fungi and were found to 
control several important plant pathogens but the natural compounds suffered from 
photoinstability. Synthetic modifications of the strobilurins have resulted in more 
stable and active compounds and the first product for agricultural use, kresoxim 
methyl (Fig. 29), was launched by BASF in 1996. The strobilurins are at present 
an important group of agricultural fungicides.
145 
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4.3.8 Diversity of structures and targets 
This background on antifungal antibiotics is in no way comprehensive but does 
present the major groups of natural products to which hopes of controlling fungal 
pathogens have been put. The survey also shows that many fungal subcellular 
processes can be targets for antifungal compounds (Fig. 30). Basically, any protein 
that is necessary for the growth of a fungal pathogen is a potential antifungal 
target. In the model fungus Saccharomyces cerevisiae, over 1100 genes have been 
found to be essential for growth on rich media.
147 This gives an indication that 
there are many potential targets which could be used for antibiotic screening. 
There are also efforts for finding genetic targets that are not part of basic fungal 
metabolism.  
One approach could be to target virulence factors. These are many times 
pathogen specific, and by only focusing on the mechanism of infection for 
pathogen control, the pressure for development of resistance is lower.
148 However, 
bioassays based on sub-cellular targets, such as interference with protein 
production or inhibition of enzymes, investigates only one range of antifungal 
modes of action. Monitoring physical interactions with existing fungal cell 
structures can also be of value, exemplified by the cell membrane association of 
the benanomicins, all syringo-peptides and the macrolides. None of these 
antibiotics would have been discovered in an enzyme-based approach.  
 
 Cell membrane  Amphotericin B (4.3.4)
  Natamycin  (4.3.4)
  Nystatin  (4.3.4)
  Pseudomycins  (4.3.2)
  Syringomycins  (4.3.2)
  Syringostatins  (4.3.2)
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Fig. 30. Antifungal antibiotics grouped according to fungal target. Numbers in parenthesis 
refer to chapters in the thesis (hyphal tip after Girbardt, ref 146).  
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5. Isolation of antifungal antibiotics 
This chapter presents an introduction to a selection of useful methods and 
techniques associated with natural product chemistry. Any thorough descriptions 
of the methods was outside the scope of the thesis, and the interested reader will 
find further reading in the review articles and books cited in this section. 
 
5.1 Bioassays 
In 1972, the first antifungal bioassay based on a sub-cellular target was published 
by Ragsdale and Sisler.
149 They presented an assay monitoring ergosterol 
inhibition in the smut Ustilago maydis. Although they did not target a specific 
enzyme in ergosterol biosynthesis, the approach was definitely new, in comparison 
with earlier assays which monitored inhibition of the whole pathogen cell, or 
spore. They presented a single-target specific bioassay in contrast to the earlier 
multi-target functional bioassays.
150 
Another way to categorize bioassays is into in vivo and in vitro bioassays, where 
the in vivo assays more closely resembles the system where the tested agent should 
be used.
151 In agriculture, an in vivo assay could mean spraying a potential 
antifungal agent on living plants infected with a fungal pathogen, or compare 
incidence of natural infection between non-treated fields with treated fields. 
Clearly, in vivo assays of this kind are not well suited for rapid bioassay-guided 
isolation of antifungal antibiotics. Too much material is needed, they are very 
space consuming, and assay cycle time might be very long. Instead, different types 
of in vitro assays are used. Taking an antifungal agent all the way to the market 
does, however, include in vivo assays but keeping them to a minimum will save 
both time and money.  
The  in vitro assays can be divided into diffusion and dilution assays.
152 In 
diffusion assays, the sample needs to diffuse through a solid medium which also 
contains the test organism. The classical diffusion assay consists of placing a paper 
disk soaked with the test compound on an agar plate inoculated or plated with 
fungal spores, or pipetting a solution of the sample to a small well in the agar plate. 
The size of any mycelium-free zone around the sample after inoculation is used as 
the bioassay reading. Agar is compatible with hydrophilic and moderately 
lipophilic compounds but highly lipophilic compounds and charged compounds do 
not diffuse well. For lipophilic compounds normal phase TLC plates have been 
used as solid support,
153 although it has been proposed that minimal inhibitory 
concentration (MIC) values from this method might be overestimated in 
comparison with other assays.
151 Diffusion assays are very versatile and do not 
require expensive equipment. However, the observed biological activity is hard to 
correlate to exact concentrations of the test compounds as the inhibition zones 
depend on concentration gradients. The relative large size of the individual assays 
also makes it laborious to test many samples.  
In dilution assays the test organism or sub-cellular target is suspended in a 
solution where the sample concentration can be controlled. Solubility of the 
samples may pose a problem and can be improved by additions of detergents or   31 
organic solvents at levels that do not affect the assay organism too much. Dilution 
assays are easily adapted to automation and can be used with microtiter plates in 
the 96 (Papers I-IV), 384, and even 1536 format. Most enzyme-based assays 
belong to this category, as well as the dilution microtiter bioassay used in the work 
of this thesis (see Chapter 7.3), where testing is done on cell free supernatant of 
microbial liquid cultures. 
 
5.1.1 Bioassays in chemical investigation of BCAs 
Chemical investigation of potential BCAs is aimed at identifying known, as well as 
new antibiotics. An ideal bioassay should therefore be non-specific in terms of 
mode of action. It should be able to detect antifungal and fungistatic effects 
regardless of what fungal enzyme might be inhibited or whatever physical barrier 
in the fungus that is affected, i.e. it should be a multi-target functional bioassay. 
This can be achieved by basing an assay on inhibition of fungal cell growth or 
fungal spore germination.  
 
5.2 Dereplication 
Dereplication in natural product screening means early elimination of uninteresting 
entities. By removing them from investigation, time is saved. The process can be 
done at different stages in the screening process, both in selection of strains and 
during isolation. Entities that should be removed are non-active strains, excess 
numbers of metabolically similar strains etc. In isolation, known compounds are 
the main target for dereplication. Strain and compound dereplication is many times 
overlapping. To speed up dereplication, a reference database is very useful, may it 
be commercial or set up by the individual research group.  
 
5.2.1 Strain dereplication 
Genetic similarity of microorganisms is expected to mirror similarity in metabolite 
production, virulence and overall performance. For bacteria, the preferred part of 
the genome to base comparison on is the gene for the 16s subunit of the ribosome 
(16s rDNA) or the corresponding RNA (16s rRNA). This most often provides 
resolution at the genus level. For fungi, the internal transcribed spacer (ITS) region 
is widely used. Any obtained sequence can be compared in-house and with online 
database collections such as GenBank.
154 
Strain dereplication can also be achieved by looking at the expression of 
metabolites directly, i.e. metabolic profiling. Methods used includes screening with 
ESIMS of extracted agar plugs,
155 GC-MS of volatile metabolites,
155 direct 
injection in ESIMS of SPE concentrated liquid supernatant,
156 liquid-liquid 
extracted supernatant
157 and MALDITOF of whole bacterial cells
158. Several NMR 
screening protocols have also been applied.
159,160 The data can be interpreted in 
two different ways. Either the data is analyzed for presence of specific known 
metabolites and a decision is taken whether the strains are interesting for further 
investigation, or the data is used for grouping strains according to metabolic 
similarity, and strains are selected depending on their position in the cladogram, 
PCA plot etc. However, the most important dereplication process when working   32
with potential BCAs, is selection for strains that perform well in bioassays, thus 
deselecting strains without biological activity.  
 
5.2.2 Compound dereplication 
In compound dereplication there is always a trade-off between speed and accuracy. 
The less data used to identify a compound, the faster will dereplication proceed but 
the risk of discarding interesting hits will also increase. Identification could be 
based on mass spectra, MS fragmentation patterns, HPLC retention times, UV 
absorption spectra, 
1H NMR spectra or any combination of these. Large databases 
exist for on-line identification of compounds by EIMS but as EI ion sources are 
not suitable for HPLC coupling they are not of much help for rapid dereplication 
of strains grown in liquid culture. Useful databases include Antibase, MarinLitt, 
CASonline and the Dictionary of Natural Products. However, dereplication 
depends on manual comparison of own data with the databases and any automation 
is normally achieved by building an own in-house database.
161 Efforts towards 
standardization or cross-platform compatibility would be much appreciated. 
 
5.2.3 Dereplication in search of BCAs 
For a microbial biocontrol agent, the performance in the field is the most important 
trait. The organism needs to survive long enough to exert its effect on any 
pathogen. One way of improving the chances for this is to collect strains for 
screening from sites that are similar to the sites where a possible end-product will 
be used. When targeting agricultural pathogens in a temperate climate this 
approach rules out the use of extremophiles, and to a certain extent also 
endophytes. Instead, the best places to look are the classical rhizosphere and 
phyllosphere. In order to obtain representative or unique strain collections from 
these sources, one must apply unique isolation protocols. This could include use of 
specific isolation media, physical thresholds or selection on morphological traits, 
as well as early field trials or greenhouse trials.  
If specific isolation protocols are used when collecting strains, there is a high 
probability of isolating many similar strains, which means that strain dereplication 
is essential before chemical investigation. However, a collection of similar isolates 
can also be an asset as minor genetic differences can influence traits as viability, 
tolerance of storage or virulence.  
 
5.3 Sample preparation and isolation 
Bioactive natural products are often present in low concentrations. In extreme 
cases, metabolites can accumulate up to a few percent of organism dry weight or 
growth medium, but often the concentrations are much lower, usually at the ppm 
or sub-ppm level. Different types of sample preparation are needed for removing 
the bulk matrix and concentrating the metabolites prior to chromatographic 
separation.
162 Traditionally, liquid-liquid extraction has been used for extracting 
metabolites and the method is well suited for working with extracts from solid or 
liquid matrix. The main drawbacks are high consumption of organic solvents and   33 
difficulties in automatization. When working with liquid microbial cultures, solid 
phase extraction (SPE) is a good alternative.  
 
5.3.1 Solid phase extraction 
Solid phase extraction (SPE)
163 relies on the same principles as all other 
chromatographic techniques; the distribution of the analyte between a stationary 
phase and a mobile phase. There exists a plethora of stationary phases for SPE, 
spanning most chromatographic separation mechanisms. In natural products 
isolation, octadecyl-bonded silica (ODS, or more commonly C18) is a useful 
material for isolating analytes of a wide lipophilic range. This can be 
complemented with graphitized carbon or short-chain alkyl-bonded silica for less 
lipophilic compounds. The solid phase comes in pre-packed disposable columns 
and in bulk for packing columns of desired size.  
The aqueous sample solution is passed through the column and the analytes are 
adsorbed on the stationary phase. The material is then desorbed with a small 
amount of organic solvent. This results in a concentrated lipophilic fraction and a 
hydrophilic fraction with the same size as the loading volume. SPE has very low 
resolution when compared to HPLC and is used as a kind of digital or discrete 
chromatography. Either a specific compound is adsorbed on the column during 
sample loading (ON), or passes right through. The column is then eluted with 
different solvent, and the adsorbed compound is either displaced (OFF) or is still 
bound to the column. Any intermediate results are unwanted. The technique is 
easily automated
164 and makes use of small amounts of organic solvents. 
 
5.3.2 High performance liquid chromatography 
High performance liquid chromatography (HPLC)
165 is a standard analytical and 
preparative technique for fractionating complex samples to obtain pure analytes. 
Separation of samples in HPLC depends on the choice of stationary phase, mobile 
phase, temperature and flow rate. The C18 stationary phase is, as in SPE, a default 
starting point in sample isolation. The mobile phase is usually a combination of 
water and a miscible organic solvent such as MeOH or MeCN. A common 
modification of the mobile phase is control of pH by acids or bases and organic or 
inorganic buffers. The HPLC system can be coupled to a number of detectors 
depending on the type of samples analyzed. Common detectors are refraction 
index (RI), UV/VIS, and MS detectors, of which the two latter are often combined. 
The more information present of the analyte, the more specific detection methods 
can be used in order to increase sensitivity.  
Purification of complex samples on HPLC, such as SPE-fractions from culture 
broths, is preferentially started with a standardized gradient run that will give a 
coarse fractionation of the sample based on lipophilicity. The next HPLC step (or 
steps) is concentrated on developing an isocratic or gradient method that will 
separate the compounds into pure fractions. 
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6. Structure elucidation  
A compound is described by its atoms and how they are connected to each other. 
The bonding pattern (compound skeleton) and the atoms’ spatial arrangement 
(absolute configuration) need to be elucidated. Compound conformation is 
normally not necessary for unambiguous description. When the antibiotic era 
started, structure elucidation depended heavily on compound degradation and 
derivatization, but since the sixties spectroscopic and spectrometric methods are 
dominating. In natural products chemistry, NMR and MS are often sufficient to 
determine the compound skeleton. IR, which can identify functional groups and 
carbon hybridization level, has been phased out, and is mainly used as a compound 
characterization method, together with optical rotation, UV absorbance and 
melting point. In determination of absolute configuration, the method of choice is 
dependent on the properties of the investigated compound. A short presentation of 
MS, NMR, and two approaches to determine absolute configuration, is listed 
below.  
 
6.1 Mass spectrometry 
In mass spectrometry (MS) the investigated species is ionized and detected by its 
specific mass to charge ratio (m/z). The output data gives information on the 
monoisotopic mass of the investigated species. If the ionization technique is soft, 
like in electrospray ionisation (ESI) and matrix-assisted laser desorption/ionisation 
(MALDI), the molecular ion or pseudomolecular ion is present at high intensity. 
Soft ionization is often combined with one or several fragmentation step on 
selected molecular ions to yield more information on the species. In high energy 
ionization like electron impact (EI), most molecular ions are fragmented and 
fragment ions are presented in the mass spectrum. The high fragmentation pattern 
reproducibility in EIMS makes it possible to use the compound mass spectrum as a 
fingerprint.  
If the mass analyzers have sufficiently high resolution, the data can be used to 
calculate the elemental composition of the species, because of the minute 
differences in mass of neutrons and protons, together with the small mass addition 
of electrons. Mass analyzers with high resolution include sector instruments, some 
time-of-flight (TOF)-instruments, and the gold standard Fourier transform ion 
cyclotron resonance (FT-ICR) instruments.  
Very often the mass spectrometer is hyphenated to a chromatographic system, 
for separation of complex samples before MS analysis. For HPLC, the standard is 
coupling to an ESIMS while GC is compatible with EIMS. Mass spectrometry is a 
destructive technique but most variants are very sensitive, requiring only 
micrograms or nanograms for analysis.  
In compound isolation and identification, mass spectrometry fills many 
functions. It can be used for scanning complex samples for specific compounds, 
either directly in mixture, or by using the mass spectrometer as a detector in a 
chromatographic system (HPLC-ESIMS, GC-MS). It can also indicate (ESIMS, 
EIMS, MALDITOF) or verify (high resolution techniques) compound elemental composition. Multiple stage mass spectrometry can aid structure elucidation [ion-
trap (IT) ESIMS
n, post source decay (PSD) MALDITOF and Q-TOF], e.g. in 
sequencing of peptides. 
 
6.2 Nuclear magnetic resonance spectroscopy 
Certain nuclei have a magnetic spin, which can be manipulated by an external 
magnetic field. This is made use of in nuclear magnetic resonance (NMR) 
spectroscopy. The spin possessing nuclei of main interest in natural product 
structure elucidation are 
1H, 
13C, 
15N and to some extent 
31P. By using one and 
two-dimensional NMR techniques the carbon-hydrogen bonding pattern can be 
elucidated. NMR is a non-destructive technique but sensitivity is lower than for 
MS. One way to achieve higher sensitivity, is to use a stronger magnetic field. At 
present, field strengths corresponding to a proton frequency of 400-900 MHz are 
widely used. If the sample tube is narrow, the sensitivity will be high, as less 
solvent can be used and the receiving coils can be placed closer to the sample. This 
is the reason for development of probes with smaller and smaller sample volumes. 
Use of a cryo-probe, which reduces noise by cooling the electronics, will also 
boost sensitivity significantly. With a 600 MHz NMR spectrometer, equipped with 
a 2.5 mm non-cryo microprobe (45 μl sample volume), less than a micromole is 
often sufficient for elucidation. 
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Fig. 31. Different 
1H-
1H and 
1H-
13C correlations achieved by standard NMR pulse 
programs, exemplified on pseudotrienic acid B (Paper II). 
 
A standard set of NMR experiments is normally used to elucidate an unknown 
structure (Fig. 31). One-dimensional 
1H NMR gives a picture of the hydrogens of 
the sample and proton-proton coupling constants. Two-dimensional homonuclear 
(
1H,
1H) experiments show proton spin systems (COSY and TOCSY experiments) 
or can identify through-space correlations between protons (ROESY and NOESY 
experiments). Two-dimensional heteronuclear (
1H,
13C) NMR will display one-
bond correlations between carbons and protons (HSQC experiments) or two-bond 
to four-bond correlations between carbons and protons (HMBC experiments). 
There are many other experiment to produce specific data (two-bond to four-
bond proton-carbon coupling constants, chemical exchange etc.). A good 
introduction article on how to apply NMR in natural products chemistry is the 
review article by Reynolds and Enriquez.
166  
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6.3 Absolute configuration 
Many biochemical processes depend on chirality, i.e. that the reaction has a 
defined stereochemistry. One enantiomer will be able to participate in the reaction 
while the other might not react. This is exemplified by the consistent inclusion of 
only L-amino acids in human proteins. Certain microorganisms, on the other hand, 
make use of only the L form of some amino acids and only the D form of other. 
The handedness of biochemistry makes it logical to expect that a metabolite 
containing chiral centers should be biosynthesized in only one configuration. 
Determination of absolute configuration is thus an important part of structure 
elucidation. However, stereocenters in isolated natural products can lack 
enantiomeric excess due to rearrangements, non-stereospecific hydrolysis or 
oxygenation  etc., which could occur spontaneously or be induced during the 
isolation process.  
Two approaches in investigation of absolute configuration are enantiomeric 
resolution methods and different NMR techniques. In addition to these, which are 
presented below, there are also other ways to determine absolute configuration. X-
ray crystallography is the gold standard, if one only can produce crystals of 
sufficient quality of the compound. Circular dichroism and optical rotation can be 
calculated from hypothesized structures
167 and compared with experimental data. 
Another approach is through stereoselective synthesis and then physico-chemical 
comparison with the natural material. If the natural product holds for comparison, 
it is often seen as the definitive proof of correct structure assignment.
168 
 
6.3.1 Enantiomeric resolution methods 
Enantiomeric resolution is achieved by derivatizing a chiral compound of interest 
with an enantiomerically pure reagent. The derivatized compound is then 
compared with standards to verify absolute configuration. The raison for 
enantiomeric resolution is that diastereomers do not have identical physico-
chemical properties. They can thus often be separated by chromatography on a 
non-chiral system. The need for standards means that natural products are often 
too complex to analyze directly, and have to be degraded to yield small chiral parts 
for analysis. However, caution is recommended when degrading a compound, as to 
not induce racemization of the chiral centers. One examples of an enantiomeric 
resolution methods is the advanced Marfey’s method
169,170 for defining absolute 
configuration of amino acids (Paper I). It is based on derivatization with 1-fluoro-
2,4-dinitrophenyl-5-L-alanine amide (FDAA) and subsequent analysis with HPLC-
UV or HPLC-ESIMS. A second example is the method for 2-hydroxy and 3-
hydroxycarboxylic acids used in Paper II.
171 
 
6.3.2 NMR 
When several stereogenic carbons are immediately bound to each other, or if they 
are part of a rigid ring, there is often a possibility to determine the relative 
configuration by NMR. This can be done by using the relationship between three-
bond coupling constants between protons, two-bond couplings between protons 
and carbons, and the dihedral angle described by the Karplus equation. This   37 
method has been named J-based configuration analysis
172 and specific pulse 
programs can be applied measuring the size of small two-bond proton-carbon 
couplings
173. Determination of relative configuration is also helped by NOESY and 
ROESY experiments which give information on relative proximity in space 
between protons. When relative configuration is solved, only one chiral center in 
the cluster has to be determined to solve the stereochemistry of all connected 
centers, thus saving a lot of time.  
The Mosher method is a type of enantiomeric resolution method for defining 
absolute configuration of stereogenic carbons with an attached hydroxyl group. 
Mosher ester derivatization
174 and the modified Mosher method
175 are based on 
derivatizing the alcohol with both R and S enantiomers of arylmethoxy acids. 
Comparing the chemical shifts of the R and S diastereomeric derivatives with a 
model of preferred conformations will indicate whether the hydroxylated carbon is 
R or S. For a review on the Mosher method, see the review article of Kusumi and 
Ohtani
176. In analogy with the Mosher method, NMR can also be used for 
determination of absolute configuration in amines and carboxylic acids.
177  
 
7. Results and discussion  
Chapters 7.1-7.4 describe the microbial material and the bioassay-guided isolation 
method, and chapters 7.5-7.8 present the isolated antifungal antibiotics. For a more 
detailed account of the antifungal antibiotics, the reader is referred to the 
individual Papers I-IV. 
 
7.1 Microbial sources  
The starting point for all projects were different collections of organism strains 
exhibiting antifungal effect in one or several types of bioassays. For each project, 
five to ten strains were selected for chemical investigation. As the collections and 
biological data present for the individual strains differed, it made it possible to see 
if the construction of the collections would influence the outcome of chemical 
investigation. Four different collections were used. 
 
1.  A diverse collection of phyllosphere microorganisms undergoing 
identification at the same time as chemical investigation (Paper I).  
2.  A collection of rhizosphere bacteria isolated by selection for growth 
under cold conditions, identified to the genus level (Paper II). 
3.  A collection of rhizosphere microorganisms identified to the genus or 
species level (Paper III). 
4.  A collection of mycorrhizal root inhabiting microorganisms identified to 
the genus or species level (Paper IV). 
 
For collection one, the five strains showing highest inhibition in the bioassays 
were selected. In collection two, ten strains with high results in the bioassays were 
investigated. In order to avoid sister isolates they were selected through colony morphological traits. For collection three, eleven strains were selected on bioassay 
performance, and avoiding sister isolates while eight strains from collection four 
were selected in the same way.  
 
7.2 Sample preparation and isolation 
A robust non-specific sample preparation method was developed, which could be 
applied to both fungi and bacteria (Fig. 32). It was based on the use of liquid 
biological material, SPE, HPLC and a dilution microtiter bioassay (Papers I-IV). 
All organisms were grown in liquid nutrient media after which the organism was 
mechanically removed. Bacteria were removed by centrifugation at 4 °C (Papers II 
and III) or by filtration under reduced pressure (Paper IV), and filamentous fungi 
by filtration under reduced pressure (Paper I). The organisms were stored as 
reference at -20 or -70 °C for possible later extraction while the supernatant was 
immediately processed or stored at +6 °C (Paper IV), -20 °C (Paper I) or -70 °C 
(Papers II and III).  
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Fig. 32. Schematic view of the bioassay-guided sample preparation and isolation method. 
Numbers on the right indicate typical amounts of sample in each step. 
 
To prepare the biological material for HPLC, it was subjected to C18 SPE to 
produce one hydrophilic fraction and one lipophilic fraction. About 20-40 g SPE 
material was used per liter supernatant, depending on whether defined or complex 
liquid medium had been used. The SPE fractionation was done either with 
prepacked 10 g-columns or columns of sufficient size prepared with bulk SPE 
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material. After loading the supernatant on the column, the hydrophilic compounds 
were washed out with aqueous 5% MeCN and pooled with the loading eluate. 
Then the lipophilic compounds were eluted with aqueous 95% MeCN. The use of 
aqueous 95% MeCN instead of 100% MeCN in eluting the lipophilic fraction was 
to avoid elution of compounds that later would adsorbing irreversibly to the HPLC 
columns. 
Both SPE fractions were tested for biological activity. An active lipophilic 
fraction was subjected to gradient HPLC on a C18-column which was followed by 
gradient or isocratic HPLC on active fractions with C18 or graphitized carbon 
column. The endpoint was an isolated pure compound. In this thesis, all isolated 
compounds came from the lipophilic fraction. All HPLC eluates were collected in 
96-well plates with a 2 ml well capacity at five fractions per minute.  
In re-isolation of compounds, the scheme was sped up by relying on the first 
isolation parameters; bioassays were routinely skipped, the SPE elutions were 
modified to obtain less material for HPLC preparation, and when possible, 
isocratic HPLC systems were applied directly after SPE to save one fractionation 
cycle.  
 
7.3 Bioassays 
The biological activity of sample fractions was followed by a previously described 
dilution microtiter bioassay.
178-180 It was based on the 96-well microtiter format 
where cells or fungal spores were co-inoculated with samples in liquid nutrient 
media. After inoculation, inhibition of cell growth and spore germination was 
estimated by the naked eye or by an automated plate reader. 
In the bioassays of chromatographic fractions, replicates of the 2 ml 96-well 
plates from preparative HPLC were done by transferring aliquots to microtiter 
plates, from which the solvents were evaporated in a fume hood overnight. To 
each well was added 100 µl of spore or cell suspension in appropriate culture 
medium. Due to the concentration achieved in the SPE step, the transferred sample 
amount corresponded to 100-400 times higher sample concentration in the 
bioassay than in the culture supernatant.  
Although the projects were aimed at isolation of antifungal antibiotics, several 
pathogenic bacteria were also used as bioassay microorganisms, in both isolation 
and determination of MIC values. This was done in order to obtain information on 
the specificity of any antimicrobial activity. In total, eleven different pathogens 
were used in the projects (Table 1.). 
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Table 1. Microorganisms used in bioassay-guided isolation, and determination of minimal 
inhibitory concentrations (MIC) 
 
Pathogen Type:  Use: 
 Organism  Indication
a Isolation MIC 
Aspergillus fumigatus  Fungus  A, H    II, III, IV  
Botrytis cinerea  Fungus A  I  I 
Candida albicans  Fungus  H  III  II, III, IV 
Drechslera sorokiniana  Fungus  A  II  II, III, IV  
Erwinia carotovora  Bacterium A    IV 
Fusarium culmorum  Fungus  A  II, III  II, III, IV  
Heterobasidion annosum  Fungus A    II 
Microsporum canis  Fungus H    II 
Pseudomonas sevastanoi  Bacterium  A    II, III, IV  
Pseudomonas syringae  Bacterium A    II 
Staphylococcus aureus  Bacterium  H  II, III,  II, III, IV 
 
aH = human pathogen, A = agricultural pathogen 
 
7.4 Project priorities 
There were three main parameters that influenced how to prioritize microbial 
strains during chemical investigation; lack or loss of antifungal activity, isolation 
of known antifungal metabolites and the limitations of lab-scale cultivation. 
 
7.4.1 Stability of the biological activity 
Some strains did not show detectable inhibition after SPE fractionation and for 
others, the activity found after SPE was lost after the first or second HPLC step. 
Thus, there was need for a fast routine to check if any found activity was 
reproducible. If antifungal activity was verified up to HPLC fractionation for three 
consecutive batches, investigation of the strain was continued.  
There are several possible explanations for loss of activity. The antifungal 
activity after SPE or the first crude HPLC step could be due to synergistic effects 
of co-eluting metabolites. As they would be separated by further (isocratic) 
chromatography, synergy would be lost. Consecutive isocratic HPLC steps in itself 
lowers concentration of an active metabolite in the bioassay as it produces broader 
peaks. The material is then eluted over a larger number of fractions. Degradation 
or modification of the active component during the isolation process is also a 
possible cause for vanishing activity. This means that strains in which the activity 
was lost could still be worthwhile investigating by applying more specialized 
sample work-up methods. 
Loss of activity was found for all types of organisms. Bacterial examples include 
pseudomonads from the Paper II collection and several strains of pink pigmented 
facultative methylotrophs (PPFMs) from the collection used in Paper III. Examples 
of fungi include several asexual white basidiomycete (AWB) strains (3035 and 
3041),
181 and  a Chaetomium hispanicum strain 704 from the collection used in 
Paper IV. 
 7.4.2 Previously isolated compounds 
In several of the projects, previously described antifungal compounds were 
isolated. Some of them were published together with new compounds found from 
the same strain (Papers I-IV). Other were duly noted after which the investigation 
of the strain was closed. In one case, citrinin, a production optimization study of 
the compound was done.
182  
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Fig. 33. Previously reported antifungal antibiotics, which were isolated in the projects. 
 
Radicicol  
 
Radicicol or monorden (Fig. 33), was isolated from Cylindrocarpon sp. F23
183 
from the Paper I collection, on its activity against Botrytis cinerea. Radicicol was 
first isolated in 1953
184 and its structure was elucidated on material isolated from 
Cylindrocarpon radicicola and Neocosmospora tenuicristata.
185,186 Radicicol has 
been reported to be active against several fungal pathogens, including Fusarium.  
 
Citrinin 
 
Citrinin (Fig. 33) was isolated from a Penicillium janczewskii strain found to 
inhibit the root-rot pathogen Heterobasidion annosum.
182 Citrinin was isolated as 
early as 1931 and is produced by Penicillium citrinum and aslo by several 
Aspergillus spp. 
187-190 This polyketide is known for its antifungal activity.
191 If 
citrinin id isolated in an aqueous environment, it is hydrated and exhibits a 
characteristic doubled 
1H NMR spectrum due to the ~ 2:1 ratio of the formed 
diastereomers. 
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Viscosin 
 
Viscosin (Fig. 33) was isolated on its activity against Fusarium culmorum from a 
Pseudomonas fluorescens MF588
192 from the Paper II collection. Viscosin
193-195 is 
a lipodepsinonapeptide, i.e. it has the same basic structure as the pseudomycins 
and syringo-peptides. It has mainly been investigated for its surfactant properties, 
but has also been reported as an antifungal and antibacterial.
196 
 
7.4.3 Material priorities 
In the projects, the maximum volume of liquid supernatant that could be produced 
and handled under standard conditions was four to eight liters, and if additional 
material was needed, new batches were started. During a project, the total amount 
of supernatant to be processed was at the most a few tens of liters. In 
characterization of a compound, the bottleneck was to produce enough material for 
heteronuclear NMR-experiments. The amounts needed for this would also be 
enough for MIC determinations on several pathogens at the 50 μg/ml level. No 
strain investigation was stopped due to too small amounts of material. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7.5 Compounds from phyllosphere fungi (Paper I) 
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Enniatin J1
a 1 Me  i-Pr Me 
Enniatin B  2  Me  i-Pr  i-Pr 
Enniatin B4 3 Me  i-Pr i-Bu 
Enniatin B1 4 Me  i-Pr s-Bu 
Enniatin B2 5 H  i-Pr i-Pr 
Enniatin K1
a 6 Me  i-Pr Et 
Enniatin J2
b 7 Me  s-Bu  Me 
Enniatin J3
b 8 Me  Me  s-Bu 
 
Fig. 34. Enniatins isolated from Fusarium sp. F31.
 aNot previously isolated from a natural 
source. 
bNot previously reported. 
 
7.5.1 Source 
The fungal strain Fusarium sp. F31 (Nectriaceae) was isolated from needles of a 
Pinus sylvestris L. (Pinaceae) plant collected in a Swedish forest nursery. The 
fungus was grown in liquid Hagem medium on a rotary shaker. The cell-free 
culture was subjected to SPE followed by gradient preparative HPLC (Fig. 35). 
Further purification yielded eight enniatins (Fig. 34).  
 
7.5.2 Structure elucidation 
The compounds were found to consist of three alternating N-methylated amino 
acids (AA) and three hydroxy acids (HA) each. The primary sequence of the 
compounds was not deducible from NMR due to lack of N-hydrogens and 
overlapping signals in the HMBC spectra. Instead, multiple stage MS was 
performed to elucidate the primary sequence. Multiple stage mass spectrometry of 
the pseudomolecular ion [M+Na]
+ revealed the sequential loss of any included 
AA, one HA, and any remaining AA. As ring-opening of depsipeptides in the 
presence of sodium has been found to take place at an ester bond,
197 this proved 
the alternating sequence of HA and AA in the compounds.  
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Fig. 35. Preparative gradient HPLC chromatogram of the 95% MeCN SPE-fraction from 
Fusarium sp. F31. Pure medium subjected to the same sample work-up is included for 
reference (both runs 10 to 100% MeCN in ten minutes with a hold at 100% for eight 
minutes).  
 
One isolated fraction was found to contain two different enniatins, J2 and J3, 
containing the same moieties and only differing in primary sequence. Attempts to 
isolate the compounds were unsuccessful and MSMS of the mixture was not 
applicable for determining the primary sequence as resulting fragments from both 
enniatins would have the same mass. In order to verify the alternating sequence of 
J2 and J3, the mixture was partially hydrolyzed, and the resulting linear 
depsipeptides were isolated. Multiple stage MS then proved the opposite primary 
sequences of J2 and J3.  
Determination of the absolute configuration of enniatins K1, J1, J2, and J3 was 
performed in two steps. The amino acids were investigated with the advanced 
Marfey’s method,
169,198 and the hydroxy acids were determined with an 
enantiomeric resolution method based on derivatization with (S)-2-butanol and 
analysis with GCMS.
199 
 
7.5.3 Biological activity 
The enniatins were tested for inhibition of Botrytis cinerea spore germination and 
showed moderate activity, with detectable inhibition down to 25 μg/ml, and total 
inhibition down to 100 μg/ml. Enniatins are reported to have phytotoxic,
200 
antimicrobial
201 and insecticidal
202 activities and they also inhibit the enzyme acyl-
Co-A:cholesterol acyltransferase.
203 In addition, they have been found to be toxic 
to mammalian cell lines and mitochondria.
204  
In agriculture, enniatins are seen as a potential toxic hazard as pathogenic 
Fusarium  species infect small-grain cereals, which results in mycotoxin 
accumulation, including enniatins.
205 On the other hand, a mixture of enniatins, 
fusafungine, is sold as a nasal spray under the name Locabiotal as an antibiotic and 
anti-inflammatory agent for treatment of nose and throat infections.
206 The broad 
  44activity of enniatins have been coupled to the compounds well established 
ionophoric properties which can destroy membrane potentials.
207 
 
7.5.4 Remarks 
Enniatins are produced by the multifunctional nonribosomal peptide synthetase 
(NRPS) enniatin synthetase which is present in many Fusarium spp.
208 Enniatin 
synthetases show different specificity for certain amino acids,
209 which can explain 
the range of enniatins isolated from Fusarium and other sources. The substrate 
specificity for the Fusarium sp. F31 enzyme was found to be similar to Fusarium 
scirpi enzymes.
210 
 
7.6 Compounds from rhizosphere bacteria (Paper II)  
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Fig. 36. Antimicrobial compounds isolated from Pseudomonas sp. MF381-IODS.  
 
7.6.1 Source 
The bacterial strain Pseudomonas  sp. MF381-IODS (Pseudomonadaceae) was 
isolated from the roots of a Brassica rapa subsp. rapa L. (Brassicaceae) plant 
collected in Switzerland.
211 It was grown on a Mineral Medium for Pseudomonas 
on a rotary shaker. The cell-free culture was subjected to SPE followed by gradient 
preparative HPLC (Fig. 37). Further purification yielded pseudotrienic acid A and 
B, 2,3-deepoxy-2,3-didehydrorhizoxin (DDR), and pyrrolnitrin (Fig. 36).  
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Fig. 37. Preparative gradient HPLC chromatogram of the 95% MeCN SPE-fraction from 
Pseudomonas sp. MF381-IODS. Pure medium subjected to the same sample work-up is 
included for reference (both runs 10 to 100% MeCN in ten minutes with a hold at 100% for 
eight minutes). 
 
7.6.2 Structure elucidation 
The carbon skeleton of the pseudotrienic acids was elucidated by NMR and MS. 
The trans configuration of all double bonds was indicated by NOE experiments 
and by the size of the three bond coupling constants. NOE correlations also help to 
define the relative configuration of C-11 and C-12 to (R,S)*.  
The (11S,12R) configuration was determined with an enantiomeric resolution 
method on the central γ-amino acid, which was released through acidic hydrolysis. 
The amino acid was derivatized with (S)-2-butanol, pentafluoropropionic 
anhydride and analyzed by GCMS (Fig. 38). A hydrolysed authentic sample of 
Bistramide A, which contains the γ-amino acid moiety with a (2S,3R) 
configuration, was used as a standard.  
The stereogenic C-20 was found to be present as R and S in equal amounts. This 
was determined by an enantiomeric resolution method for determination of 2-OH 
and 3-OH carboxylic acids. The method was based on O-methylation and 
derivatization with (S)-phenylethylamine.
171 To access the C-20 as part of a 
hydroxy acid pseudotrienic acid B was ozonolysed followed by oxidative work-up. 
This released a 2-hydroxynonanoic acid with the C-2 corresponding to the 
pseudotrienic acid C-20. The ozonolysis mixture was derivatized with (S)-
phenylethylamine and compared with a racemic 2-hydroxynonanoic acid standard 
subjected to the same procedure (Fig. 38.). 
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Fig. 38. Determination of absolute configuration of pseudotrienic acid B. Reagents and 
conditions: i) 6M HCl, 110 °C, 20 h; ii) (S)-2-BuOH/AcCl, 100 °C, 40 min; iii) 
O(COCF2CF3)2, 100 °C, 40 min; iv) O3, MeOH, -20 °C, 10 min, then H2O2, AcOH, 50 °C, 
18 h, and finally MeOH/AcCl, 80 °C, 30 min; v) trimethylsilyldiazomethane, BF3, diethyl 
ether, 0 °C, 15 min; vi) KOH, MeOH/H2O 60 °C, 2 h; vii) SOCl2, benzene, 30 °C, 30 min, 
then (S)-phenylethylamine, benzene, 30 °C, 25 min. 
 
The pseudotrienic acids may derive from conjugated ring opening of a 
macrolactone. This would explain the lack of enantiomeric excess at C-20 as ring 
opening would proceed through an achiral intermediate, and such lactones have 
been isolated from a Pseudomonas fluorescens strain.
212 In acidic environment, the 
pseudotrienic acids were found to lactonize, which further indicates the 
relationship between the linear and lactonized forms.  
 
7.6.3 Biological activity 
The pseudotrienic acids inhibited the growth of Gram-positive and Gram-negative 
bacteria at a concentration of 70 μg/ml, but did not inhibit yeasts or fungi. The 
corresponding pseudotrienic acid lactones have been reported to have 
immunosuppressant activity.
212,213  
 
7.6.4 Remarks 
Although the pseudotrienic acids did not inhibit any fungal pathogens at 100 μg/ml 
they were still isolated in the bioassay-guided fractionation. This happened 
because of contamination by pyrrolnitrin or DDR in the crude pseudotrienic acid 
fraction, producing a false positive.  
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Fig. 39. Dialkylresorcinols isolated from Pseudomonas sp. Ki19. Compounds 1 and 2 have 
not been previously reported.  
 
7.7.1 Source 
The bacterial strain Pseudomonas sp. Ki19 (Pseudomonadaceae) was isolated from 
the roots of a crowberry plant [Empetrum nigrum L., (Empetraceae)] collected 
nearby Kiruna in northern Sweden. It was grown on a Mineral Medium for 
Pseudomonas on a rotary shaker. The cell-free culture was subjected to SPE 
followed by gradient preparative HPLC (Fig. 41). Further purification yielded four 
dialkylresorcinols (Fig. 39). 
 
7.7.2 Structural elucidation 
Elucidation of the compounds was performed by NMR and ESIMS. A key 
indication was the chemical shift of C-2 (δ 141) of compounds 1-4 indicating the 
position between the two hydroxy groups. Assignment of the alkyl group positions 
was done by HMBC correlations between the alkyl alpha protons and the ring 
carbons. In addition, a benzoquinone oxidation product of compound 4 was 
isolated and described (Fig. 40).  
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Fig. 40. 2-Hexyl-3-hydroxy-5-pentylbenzo-1,4-quinone, a benzoquinone oxidation product 
of resorstatin (4). 
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Fig. 41. Preparative gradient HPLC chromatogram of the 95% MeCN SPE-fraction from 
Pseudomonas sp. Ki19. Pure medium subjected to the same sample work-up is included for 
reference (both runs 10 to 100% MeCN in ten minutes with a hold at 100% for eight 
minutes). 
 
7.7.3 Biological activity 
The compounds were found to be moderately active against fungi with full 
inhibitions down to 50 µg/ml. For Gram-positive bacteria, Staphylococcus aureus 
was completely inhibited at 2 µg/ml, with detectable inhibition at 1 µg/ml while 
Pseudomonas savastanoi pv. savastanoi was more or less unaffected at the 50 
µg/ml level. The benzoquinine oxidation product inhibited Candida and 
Staphylococcus at 100 μg/ml, i.e. it was less potent than its mother compound. 
Investigation of formation of the benzoquinone indicated that it was not formed in 
the bioassay. This result suggests that the antimicrobial activity of the 
dialkylresorcinols does not depend on formation of benzoquinones during the 
bioassay. However, it does not rule out the possibility that other antimicrobial 
compounds are metabolized from the dialkylresorcinols.  
A possible mechanism for formation of benzoquinones involves oxidation over 
trihydroxylated intermediates. The oxygen radicals formed during oxidation has 
been proposed to be responsible for the DNA degradation activity found for some 
alkylresorcinols.
214,215 The DNA strand scission of alkylresorcinols has been 
shown in vitro in the presence of Cu(II)
 at alkaline pH, but has not been shown in 
vivo. Dialkylresorcinols have been reported for diverse biological activities, such 
as antibacterial and antifungal,
216,217 cytotoxic
218 and radical scavenging activity.
219 
 
7.7.4 Remarks 
The dialkylresorcinols lack antifungal specificity, and the possible degradation to 
benzo-1,4-quinones with alkylating properties rise some questions regarding 
human toxicity. On the other hand, cereals contain resorcinolic lipids in amounts 
of 0.01-0.1%, which imply that they can be generally regarded as safe (GRAS).  
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Fig. 42. Kutznerides isolated from Kutzneria sp. 744.
 aPreviously reported from this strain. 
 
7.8.1 Source 
The actinomycete Kutzneria sp. 744 (Pseudonocardiaceae) was isolated from the 
mycorrhizal roots  of a Picea abies (L.) H. Karst (Pinaceae) plant, collected in a 
Lithuanian forest nursery. The bacterium was grown on a rotary shaker in liquid 
modified Melin Norkrans medium. The cell-free culture was subjected to SPE 
followed by gradient preparative HPLC (Fig. 43). Further purification yielded nine 
kutznerides (Fig. 42).  
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Fig. 43. Preparative gradient HPLC chromatogram of the 95% MeCN SPE-fraction from 
Kutzneria sp. 744. Pure medium subjected to the same sample work-up is included for 
reference (both runs 10 to 100% MeCN in ten minutes with a hold at 100% for eight 
minutes). 
 
7.8.2 Structure elucidation 
The compounds 5-9 were determined to be cyclohexadepsipeptides containing 
several unusual amino acid moieties.  
Subunit A was determined as 2-(1-methylcyclopropyl)-D-glycine, subunit B as a 
6,7-dichloro-3a-hydroxy-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-
carboxylic acid with a (2S,3aR,8aS) configuration, subunit C as either threo (7, 9) 
or erythro-3-hydroxy-D-glutamic acid (5, 6, 8), subunit D as a straightforward O-
methyl-L-serine, subunit E as a L-piperazic acid (5,  7), (4R)-5,6-didehydro-4-
hydroxy-L-piperazic acid (6), R-4-chloro-L-piperazic acid (8), or 5,6-didehydro-L-
piperazic acid (9), and finally subunit F as (S)-2-hydroxy-3-methylbutyric acid (5, 
7) or (S)-2-hydroxy-3,3-dimethylbutyric acid (6, 8, 9). 
Carbon-nitrogen skeletons of the individual subunits were determined from 
COSY, HSQC and HMBC experiments, while the primary sequence of the 
subunits could be elucidated by ROESY correlations. To determine the absolute 
configuration of subunits A, C, D, E and F, 5-9 were subjected to hydrolysis, 
hydrogenation, derivatization with (S)-2-BuOH followed by derivatization by 
pentafluoropropionic acid anhydride and subsequent analysis by GCMS. 
Hydrogenation reduced the cyclopropyl ring in subunit A, presenting it as a tert-
leucine, while the piperazic acid (subunit E) was reduced to ornithine. Subunit D 
was demethylated during hydrolysis, transforming it to serine.  
For subunit B, ROESY experiments together with previously performed 
molecular modeling made it possible to determine the absolute configuration. 
ROESY also helped also helped determining the configuration of the different Pip 
residues of subunit E. 
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7.8.3 Biological activity 
Kutznerides 1-9 were found to inhibit Gram-positive bacteria down to 5 μg/ml and 
the fungi down to 60 μg/ml. The compounds displayed a vast span in biological 
activity with the trichlorinated kutznerides 2 and 8 being most potent and 
kutzneride 6, containing a hydroxylated piperazic acid, being least.  
Other cyclic peptides, which share one or several of the unusual amino acids 
with the kutznerides, have been reported to have diverse biological activities. In 
subunit B, the H-8a and OH at C-3a have a cis relation and they are both trans to 
H-2. This basic configuration is also present in the cytotoxic compounds 
himastatin,
220 kapakahine C
221, phakellistatin 3
222, and the nematocidal 
omphalotins B, C, and D.
223 Interestingly, kapakahine D and isophakellistatin 3, 
which instead have an all-cis relation of H-8a, OH and H-2, are reported as non-
cytotoxic.  
Hydroxylated Pip residues are found in the mentioned himastatin, as well as in 
the cytotoxic polyoxypeptin.
224 Unsaturated piperazic acids are found in the 
antimicrobial and cytotoxic aurantimycins,
225 and, albeit some of them also 3-
hydroxylated or 3-O-acetylated, in the antimicrobial luzopeptins
226  
 
7.8.4 Remarks 
The kutznerides are most likely produced by a NRPS. The reported compounds 
show variation in the three subunits C, E and F. Four types of piperazic acid were 
found, while the OHGlu was present as its threo- and erythro-form. Finally, both 
di and monomethylated 2-hydroxybutyric acid was found. In theory, all 
combinations of the found variations would yield 24 different kutznerides. Even 
though there might be biosynthetic barriers for formation of some of the 
hypothetical compounds, trace amounts of several other kutznerides were detected 
in ESIMS. Growth optimization might succeed in isolating some of the missing 
variants. 
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8. Concluding remarks 
The investigated organisms in this thesis were selected from four different strain 
collections (see Chapter 7.1). In all cases, the first criterion of selection was strong 
pathogen suppression in bioassays, while the second was to avoid genetic 
similarities. Antifungal antibiotics were isolated from strains from all four 
collections, indicating that their biocontrol ability could be due to production of 
antibiotics.  
The structural diversity of the twenty-five isolated compounds spans several 
groups: depsipeptides, lipopeptides, polyketides, and resorcinols. Some of them 
could be suspected to be antibiotic precursors, in analogy with pro-drugs, meaning 
that the activity is related to a chemical modification of the structure. This could be 
argued for the resorcinols (Paper III) where oxidation products have been shown to 
degrade DNA in vitro. In the case of the pseudotrienic acids, the likely presence of 
both the linear and lactonized compounds in a biocontrol situation calls for 
investigations to pinpoint what activities are exhibited by which form.  
Many of the isolated compounds have not previously been reported in the 
literature. This was the case for the kutznerides 5-9 from Kutzneria sp. 744 in 
paper IV. There are few reports on chemical investigations of Kutzneria so the 
probability of isolating new metabolites from this genus might be thought to be 
higher than for thoroughly investigated organisms like the pseudomonads. 
However, Papers I-III present new compounds isolated from such well-
investigated taxa: Fusarium  and  Pseudomonas. Such metabolically diverse 
organisms are still a good source for new bioactive metabolites. This fact also 
stresses that strains should not be disregarded in dereplication just because they 
belong to a well-known genus or species, as there is metabolic diversity between 
microorganisms assigned to the same taxon. Instead, dereplication should be based 
on homology of biosynthesis gene regions or actual metabolic output, i.e. the 
metabolome. If these options are not available, a selection solely based on bioassay 
pathogen suppression is to prefer.  
Many antifungal compounds reported in the last twenty years have been 
discovered in enzyme-based assays. The assays detect a narrow spectrum of 
structures with a defined mode of action. This type of screening has been 
successfully applied in, for example, the isolation of inhibitors of fungal 
sphingolipid biosynthesis (see Chapter 4.3.5) Enzyme-based assays and also the 
promising use of genome-based screening (see Chapter 4.1) need to be based on 
known modes of action. In a way, these approaches only find what is already there. 
The methodology is useful, but will become even more so, as novel modes of 
action are described, and new biosynthesis genes are sequenced. In this thesis, a 
different approach was applied by using a bioassay based on inhibition of the 
whole pathogen. The use of such a multi-functional assay helps to isolate a wide 
array of antibiotics, in comparison with a specific enzyme inhibition assay, and can 
also detect compounds with novel antifungal modes of action. 
Although the main goal in this thesis was isolation of antifungal antibiotics, 
many compounds were also found to have antibacterial activity, and in the case of 
the pseudotrienic acids, even found to have only antibacterial activity. The reason 
for inclusion of pathogenic bacteria in the isolation bioassay (Papers II and III)   54
was that it quickly established a picture of the specificity of the biologically active 
compounds. When the pure compounds were obtained, pathogenic bacteria were 
included when feasible (Papers II-IV) in order to gain a broader knowledge of the 
antibiotic spectrum. There is certainly a risk that compounds isolated on a specific 
activity are regarded as “done”, and any additional bioactivity is left unexplored. 
But if there is plenty of an isolated compound, why not test it in all possible 
obtainable bioassays? From this aspect, the compound myriocin (see Chapter 
4.3.5) is an interesting example. It was isolated both as an inhibitor of fungal 
sphingolipid biosynthesis and, independently, on its strong immunosuppressant 
activity. Along the same lines, the pseudotrienic acids in Paper II were isolated as 
antibiotics while the lactonized forms were isolated as immunosuppressants by 
another research group. 
In conclusion, this thesis shows that microorganisms able to inhibit fungal 
pathogens are good sources for antifungal antibiotics. The use of a bioassay based 
on pathogen growth makes it possible to isolate a wide range of compounds, with 
the potential of finding compounds with new antifungal modes of action. As a 
bonus, the strains in which no antifungal metabolites were found can still be 
investigated as potential biocontrol agents. 
 
8.1 Proposal for further studies 
The potential of the strain collections used in this work is far from exhausted. The 
Papers I-IV can be seen as a preliminary sampling and when further isolation of 
compounds will be done, it would benefit much to be performed on a larger scale. 
A first step would be to make the collections compatible. There exists a large 
amount of sequence data which needs to be merged for all libraries, while other 
types of data need to be produced. A rapid metabolomic screening on all strains 
based on ESIMS could be one way of producing the latter, and another could be to 
screen all strains against an extended set of pathogens. If a screening program is 
sufficiently large, it can also be argued that additional bioassays should be 
included, in order to find stray hits. This could include assays aimed at cancer, 
immunosuppression and inflammation. 
On a more specialized level, there are several areas adjacent to the scope of this 
thesis that would benefit form further research. In Paper II, the relation between 
the pseudotrienic acids and the lactonized forms needs to be clarified, both in 
terms of biosynthesis and bioactivity. The enniatins, and probably the kutznerides, 
are biosynthesized by nonribosomal peptide synthetases. Investigation of amino 
acid specificity and directed biosynthesis could in the kutzneride case possibly 
yield even further structures with antimicrobial activity.  
The compounds in Papers I-IV inhibit pathogens in vitro. The next logical 
questions are: do the compounds inhibit pathogens in the field, and are the 
compounds biosynthesized when the producing organism is applied in the field? 
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 A Taxonomic names of organisms 
A.1 Bacteria 
 
Organism
a Type of human impact  Family
a
Actinomadura hibisca Tomita et al. 1991  Pradimicin producer  Termomonosporaceae 
Bacillus cereus Frankland and Frankland 1887  Cispentacin producer  Bacillaceae 
Erwinia carotovora (Jones 1901) Bergey et al. 1923  Agricultural pathogen  Enterobacteriaceae 
Kutzneria sp.  Paper IV. Kutznerid producer   Pseudonocardiaceae 
Lactobacillus sp.  Used as probiotics  Lactobacillaceae 
Micromonospora chalcea (Foulerton 1905) Ørskov 1923  Rustmicin/galbonolid producer  Micromonosporaceae 
Mycobacterium tuberculosis (Zopf 1883) Lehmann and Neumann 1896  TBC  Mycobacteriaceae 
Pseudomonas fluorescens Migula 1895  Paper II collection. Viscosin producer  Pseudomonadaceae 
Pseudomonas sp. Ki19  Paper III. Dialkylresorcinol producer  Pseudomonadaceae 
Pseudomonas sp. MF381-IODS  Paper II. Pseudotrienic acid producer  Pseudomonadaceae 
Pseudomonas pyrrocina Imanaka et al. 1965  Pyrrolnitrin producer  Pseudomonadaceae 
Pseudomonas savastanoi (Janse 1982) Gardan et al. 1992  Agricultural pathogen Pseudomonadaceae 
Pseudomonas syringae pv. syringae van Hall 1902  Agricultural pathogen 
source of    syringomycins 
     syringotoxins 
     syringostatins 
     pseudomycins 
Pseudomonadaceae 
Sorangium cellulosum Reichenbach 2002  Soraphen producer   
               Current name: Polyangium cellulosum (ex Imshenetski and Solntseva 1936) Brockman, 1989  Polyangiaceae 
Staphylococcus aureus Rosenbach 1884    Human pathogen  Staphylococcaceae 
Streptomyces cacaoi (Waksman 1932) Waksman and Henrici 1948  Polyoxin producer  Streptomycetaceae 
Streptomyces chattanoogenis Burns and Holtman 1959  Natamycin producer  Streptomycetaceae 
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a
Streptomyces galbus Frommer 1959  Rustmicin/galbonolid producer  Streptomycetaceae 
Streptomyces griseochromogenes Fukunaga 1955  Blasticidin producer  Streptomycetaceae 
Streptomyces griseus (Krainsky 1914) Waksman and Henrici 1948  Streptomycin producer  Streptomycetaceae 
Streptomyces hygroscopicus (Jensen 1931) Waksman and Henrici 1948  Validamycin producer  Streptomycetaceae 
Streptomyces kasugaensis Hamada et al. 1995  Kasugamycin producer  Streptomycetaceae 
Streptomyces natalensis
b Natamycin producer  Streptomycetaceae 
Streptomyces setonii (Millard and Burr 1926) Waksman 1953  Cispentacin producer  Streptomycetaceae 
Streptomyces tendae Ettlinger et al. 1958  Nikkomycin producer  Streptomycetaceae 
Streptoverticillium rimofaciens
c Mildiomycin producer   
 
aAuctors, family names and species names were retrieved from the National Centre for Biotechnology Information (Tax Browser: 
http://www.ncbi.nlm.nih.gov/Taxonomy/taxonomyhome.html/) 20060420, and J.P. Euzéby: List of Prokaryotic Names with Standing in Nomenclature 
(http://www.bacterio.cict.fr/index.html) 20060420. 
bThis species name has no standing in nomenclature 
cThis species name has no standing in nomenclature. Streptoverticillium was transferred to Streptomyces 1991. 
 
A.2 Fungi 
 
Organism
a Type of human impact  Family
a Division
b
Alternaria spp.  Agricultural pathogen  Pleosporaceae  Ascomycete 
Arthrinium arundinis (Corda) Dyko & B. Sutton  Arundifungin producer     
               Current name:     Apiospora montagnei Sacc.  Apiosporaceae  Ascomycete 
Ascotricha amphitricha (Corda) S. Hughes Ascosteroside producer  Xylariaceae  Ascomycete 
Aspergillus aculeatus Iizuka  Papulacandin producer  Trichocomaceae  Ascomycete 
Aspergillus fumigatus Fresen.  Human/agricultural pathogen  Trichocomaceae  Ascomycete 
Aspergillus nidulans var. echinulatus Fennell & Raper  Echinocandin producer   Trichocomaceae  Ascomycete 
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Aspergillus rugulosus Thom & Raper  Echinocandin producer  Trichocomaceae  Ascomycete 
Aureobasidium pullulans (de Bary) G. Arnaud  Aureobasidin producer  Dothioraceae  Ascomycete 
Botrytis sp.  Agricultural/silvicultural pathogen Sclerotiniaceae  Ascomycete 
Botrytis alli Munn  Agricultural pathogen  Sclerotiniaceae  Ascomycete 
Botrytis cinerea Pers.  Agricultural/silvicultural pathogen Sclerotiniaceae  Ascomycete 
Candida albicans (C. P. Robin ) Berkhout   Human pathogen  Saccaromycetaceae  Ascomycete 
Chaetomium hispanicum Guarro & Arx  Paper IV collection  Chaetomiaceae  Ascomycete 
Cryptococcus neoformans (San Felice) Vuill.  Human patogen 
Sphingofungin producer 
Tremellaceae Basidiomycete 
Cylindrocarpon sp.  Paper I collection. 
Monorden producer 
Nectriaceae Ascomycete 
Cylindrocarpon radicicola Wollenw.  Monorden producer     
               Current name:     Nectria radicicola Gerlach & L. Nilsson  Nectriaceae  Ascomycete 
Drechslera sorokiniana (Sacc.) Subram. & B. L. Jain  Agricultural pathogen     
               Current name:     Cochliobolus sativus (S. Ito & Kurib.) Drechsler ex Dastur  Pleosporaceae   
Erysiphe graminis DC  Agricultural pathogen  Erysiphaceae  Ascomycete 
Fusarium sp.  Agricultural pathogen 
Paper I. Enniatin producers 
Nectriaceae Ascomycete 
Fusarium scirpi F. Lamb. & Fautrey  Enniatin producer     
               Current name:     Gibberella acuminata C. Booth  Nectriaceae  Ascomycete 
Fusarium moniliforme J. Sheld.  Fumonisin producer  Sclerotiniaceae  Ascomycete 
Fusarium oxysporum Schltdl.  Agricultural pathogen  Nectriaceae  Ascomycete 
Gerlachia nivalis (Ces. ex Berl. & Voglino) W. Gams & E. Müll.  Agricultural pathogen     
               Current name:     Monographella nivalis var. nivalis (Schaffnit) E. Müll.  Of uncertain position Ascomycete 
Heterobasidion annosum (Fr.) Bref.  Silvicultural pathogen Bondarzewiaceae  Basidiomycete 
Hormonema sp.  Enfumafungin producer  Of uncertain position Deuteromycete 
Isaria sinclairii (Berk.) Lloyd  Myriocin/ISP-1 producer  Clavicipitaceae  Ascomycete 
Microsporum canis E. Bodin ex Guég  Human pathogen  Arthrodermataceae  Ascomycete 
  71  72 
Organism
a Type of human impact  Family
a Division
b
Myriococcum albomyces Cooney &R. Emers.  Myriocin/ISP-1 producer     Ascomycete 
               Current name:     Melanocarpus albomyces (Cooney & R. Emers.) Arx 1975  Of uncertain position  
Neocosmospora tenuicristata S. Ueda & Udagawa  Monorden producer  Nectriaceae  Ascomycete 
Oudemansiella mucida (Schrad.:Fr.) Höhn.  Strobilurin producer Marasmiaceae  Basidiomycete 
Penicillium citrinum Thom  Citrinin producer  Trichocomaceae  Ascomycete 
Penicillium griseofulvum Dierckx  Griseofulvin producer  Trichocomaceae  Ascomycete 
Penicillium janczewskii K.M. Zalessky  Citrinin producer  Trichocomaceae  Ascomycete 
Pyricularia oryzae Cavara  Agricultural pathogen     
               Current name:     Magnaporthe grisea (T.T. Hebert) M.E. Barr  Magnaporthaceae  Ascomycete 
Pythium sp.  Agricultural pathogen  Pythiaceae  Oomycete 
Phytophthora infestans (Mont.) de Bary  Agricultural pathogen  Pythiaceae  Oomycete 
Rhizoctonia solani J.G. Kühn  Agricultural pathogen     
               Current name:     Thanatephorus cucumeris (A.B. Frank) Donk  Ceratobasidiaceae  Basidiomycete 
Rhizopus chinensis Saito  Rhizoxin producer     
               Current name:     Rhizopus microsporus var. chinensis (Saito) Schipper & Stalpers  Mucoraceae  Zygomycete 
Saccharomyces cerevisiae Meyen ex E.C. Hansen  Bakers yeast, type yeast  Saccharomycetaceae  Ascomycete 
Sordaria araneosa Cain  Sordarin producer  Sordariaceae  Ascomycete 
Sporormiella australis (Speg.) S.I. Ahmed & Cain  Australifungin producer  Sporormiaceae  Ascomycete 
Strobilurus tenacellus (Pers.) Singer  Strobilurin producer  Marasmiaceae  Basidiomycete 
Trichoderma koningii Ouderm.  Ergokonin producer  Hypocreaceae  Ascomycete 
Trichoderma viride Pers.  Viridofungin producer  Hypocreaceae  Ascomycete 
Ustilago maydis (DC.) Corda  Agricultural pathogen  Ustilaginacea  Basidiomycete 
 
aAuctors, family names and species names were retrieved from Index Fungorum (http://www.indexfungorum.org) 20060420 
bDivision affiliations based on common usage. 
 